Skip to main content
Equibles

GLAND · Gland Pharma Limited · Documents

Use GLAND with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GLAND.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
3,308.70 INR +44.80 (+1.37%) At close · Nov 12
Rebalance outlook locked
Market Cap
545.97B INR
Shares
165.01M
Volume · Nov 12 223.91K Avg daily vol (3M) 499.88K

The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →

Earnings call New Q2 2027 earnings call Held Nov 6, 2026
2026
Nov 6
Earnings call
Q2 FY27 revenue rises 23%, profit after tax rises 58%

Gland Pharma reported Q2 FY27 revenue of Rs. 18,336 million, up 23% year-on-year, and profit after tax of Rs 2,908 million, up 58% year-on-year.

3 source passages
For the second quarter of FI27, our consolidated revenues stood at Rs. 18,336 million, representing a growth of 23% year-on-year. Profit after tax for the quarters stood at Rs 2,908 million, representing growth of 58% year-on-year, despite the impact of significant higher R&D investment and temporary profitability pressure of Senexia rising from the annual shutdown period. On behalf of Gland Pharma, we conclude this conference. Open the document at this passage
Showing 1–1 of 1 documents